U.S. Markets closed

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CWH, HON, DY, ALGN and NKTR

NEW YORK, Dec. 14, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Camping World Holdings, Inc. (CWH)
Class Period: March 8, 2017 to August 7, 2018
Lead Plaintiff Deadline: December 18, 2018

Throughout the class period, Camping World Holdings, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company’s disclosure controls and controls over financial reporting suffered from a host of material weaknesses; (2) the Company’s historical financial results had been materially misstated; (3) the Gander stores had encountered integration setbacks, adversely impacting the Company’s earnings growth and profit margins; and (4) the Company’s core RV business was experiencing decelerating growth as the Company lagged industry trends and was losing market share to competitors.

Get additional information about the CWH lawsuit: http://www.kleinstocklaw.com/pslra-1/camping-world-holdings-inc-loss-submission-form?wire=3

Honeywell International Inc. (HON)
Class Period: February 9, 2018 to October 19, 2018
Lead Plaintiff Deadline: December 31, 2018

According to the complaint, Honeywell International Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Honeywell’s Bendix Friction Materials ("Bendix") asbestos-related liability was greater than initially reported; (2) the Company maintained improper accounting practices in connection with its Bendix asbestos-related liability; and (3) as a result, Honeywell’s public statements were materially false and misleading at all relevant times.  Honeywell previously owned Bendix, which used asbestos in its brake- and clutch-pad products until 2001; the Company sold Bendix in 2014.

On August 23, 2018, Honeywell announced it had "revised its method for reasonably estimating its liability for unasserted Bendix asbestos-related claims by considering the epidemiological projections through 2059 of future incidence of Bendix asbestos-related disease. Using this method, the Company’s Bendix asbestos-related liability is estimated to be $1,693 million as of June 30, 2018. This is $1,083 million higher than the Company’s prior estimation which applied a five-year horizon when estimating the liability for unasserted Bendix asbestos-related claims. The Bendix asbestos-related insurance assets are estimated to be $187 million as of June 30, 2018, which is $65 million higher than the Company’s prior estimate."

Get additional information about the HON lawsuit: http://www.kleinstocklaw.com/pslra-1/honeywell-international-inc-loss-submission-form?wire=3 

Dycom Industries, Inc. (DY)
Class Period: November 20, 2017 to August 10, 2018
Lead Plaintiff Deadline: December 24, 2018

The lawsuit alleges that Dycom Industries, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Dycom’s large projects were highly dependent on permitting and tactical considerations, (ii) Dycom was facing great uncertainties related to permitting issues; (iii) said uncertainties would expose Dycom to near-term margin pressure and absorption issues, and (iv) as a result of the foregoing, Defendants’ statements about Dycom’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

Get additional information about the DY lawsuit: http://www.kleinstocklaw.com/pslra-1/loss-submission-form-2?wire=3

Align Technology, Inc. (ALGN)
Class Period: April 25, 2018 to October 24, 2018
Lead Plaintiff Deadline: January 4, 2019

According to the complaint, Align Technology, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) at the beginning of the year the Company changed its North American Advantage Customer Loyalty Program by extending the discount qualification period from quarterly to semi-annual and created additional incentive tiers which was intended to, and did, result in “higher overall discounts” for its doctor customers and substantial reduction of the average sales price (ASP); (2) in Q3 the Company initiated a new Invisalign product promotion that resulted in substantial reduction of its ASP;  (3) the promotions and discounts would materially impact net income as a result of reduced profit margins; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Get additional information about the ALGN lawsuit: http://www.kleinstocklaw.com/pslra-1/align-technology-inc-loss-submission-form?wire=3

Nektar Therapeutics (NKTR)
Class Period: November 11, 2017 to October 2, 2018
Lead Plaintiff Deadline: December 31, 2018

The complaint alleges that throughout the class period Nektar Therapeutics made materially false and/or misleading statements and/or failed to disclose that: (1) prior studies which attempted to pegylate IL-2 failed; (2) the extended half-life of the Company's lead I-O candidate, NKTR-214, was unlikely to result in efficacy and created additional high-dosing safety concerns; (3) NKTR-214 was less effective than IL-2 alone; (4) the combination of NKTR-214 with nivolumab has yet to demonstrate significant positive results; and (5) as a result, Nektar’s public statements as set forth above were materially false and misleading at all relevant times.

Get additional information about the NKTR lawsuit: http://www.kleinstocklaw.com/pslra-1/nektar-therapeutics-loss-submission-form?wire=3

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com